ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,10179
0,58%
Bitcoin
63.739,98
-0,24%
Brent Oil
82,765
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Bausch Health Cos (VRX)

  7. Bausch Health Cos (VRX) Notícias

VRX

Valeant Pharma (VRX)

Bausch Health Cos
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:VRX
DataHoraFonteTítuloCódigoCompanhia
13/04/202107:58PR Newswire (Canada)Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane...NYSE:VRXBausch Health Cos
24/02/202108:59PR Newswire (US)Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 GuidanceNYSE:VRXBausch Health Cos
20/01/202109:00PR Newswire (US)Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Pr...NYSE:VRXBausch Health Cos
27/10/202007:58PR Newswire (US)Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular LensesNYSE:VRXBausch Health Cos
22/10/202008:00PR Newswire (US)Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeti...NYSE:VRXBausch Health Cos
23/09/202008:00PR Newswire (US)Bausch Health Releases Annual Corporate Social Responsibility ReportNYSE:VRXBausch Health Cos
09/09/202008:00PR Newswire (Canada)Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare ConferenceNYSE:VRXBausch Health Cos
31/07/202017:43PR Newswire (US)Bausch Health Resolves Legacy SEC InvestigationNYSE:VRXBausch Health Cos
21/05/202008:00PR Newswire (Canada)Bausch Health To Participate At Goldman Sachs Annual Global Healthcare ConferenceNYSE:VRXBausch Health Cos
29/04/202017:50PR Newswire (Canada)Bausch Health Announces 2020 Annual Meeting Of Shareholder ResultsNYSE:VRXBausch Health Cos
19/02/202018:40PR Newswire (Canada)Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of ...NYSE:VRXBausch Health Cos
03/02/202009:00PR Newswire (US)Ortho Dermatologics Opens 2020 Aspire Higher Scholarship ProgramNYSE:VRXBausch Health Cos
10/10/201908:58PR Newswire (Canada)Ortho Dermatologics Announces 2019 Aspire Higher Scholarship RecipientsNYSE:VRXBausch Health Cos
08/07/201909:00PR Newswire (US)Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6NYSE:VRXBausch Health Cos
05/12/201811:00PR Newswire (Canada)Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact LensesNYSE:VRXBausch Health Cos
30/10/201809:00PR Newswire (Canada)Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United StatesNYSE:VRXBausch Health Cos
11/10/201809:00PR Newswire (Canada)Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In Th...NYSE:VRXBausch Health Cos
16/07/201818:00Edgar (US Regulatory)Current Report Filing (8-k)NYSE:VRXBausch Health Cos
09/07/201809:00PR Newswire (Canada)Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%NYSE:VRXBausch Health Cos
03/07/201817:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:VRXBausch Health Cos
26/06/201809:00PR Newswire (US)Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)NYSE:VRXBausch Health Cos
18/06/201809:00PR Newswire (Canada)FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) LotionNYSE:VRXBausch Health Cos
14/06/201809:00PR Newswire (US)Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye DropsNYSE:VRXBausch Health Cos
12/06/201809:00PR Newswire (US)Bausch + Lomb Introduces Ocuvite® Blue Light Eye VitaminsNYSE:VRXBausch Health Cos
08/06/201819:00Business WireSecurities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Valeant Pharmaceu...NYSE:VRXBausch Health Cos
08/06/201818:15Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:VRXBausch Health Cos
01/06/201817:15PR Newswire (Canada)Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redempti...NYSE:VRXBausch Health Cos
31/05/201809:30PR Newswire (Canada)Salix To Highlight New Clinical Data During Digestive Disease WeekNYSE:VRXBausch Health Cos
23/05/201804:02Dow Jones NewsEx-Valeant Executive Convicted In Scheme -- WSJNYSE:VRXBausch Health Cos
22/05/201814:48Dow Jones NewsFormer Valeant Executive Found Guilty on Charges Related to Kickback SchemeNYSE:VRXBausch Health Cos
 Apresentando as notícias mais relevantes sobre:NYSE:VRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
HETA4
HERCULES PN
BOV
AZUL4
AZUL PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados